These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38456804)

  • 1. Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.
    Bashi AC; Coker EA; Bulusu KC; Jaaks P; Crafter C; Lightfoot H; Milo M; McCarten K; Jenkins DF; van der Meer D; Lynch JT; Barthorpe S; Andersen CL; Barry ST; Beck A; Cidado J; Gordon JA; Hall C; Hall J; Mali I; Mironenko T; Mongeon K; Morris J; Richardson L; Smith PD; Tavana O; Tolley C; Thomas F; Willis BS; Yang W; O'Connor MJ; McDermott U; Critchlow SE; Drew L; Fawell SE; Mettetal JT; Garnett MJ
    Cancer Discov; 2024 May; 14(5):846-865. PubMed ID: 38456804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of the NCI-60 Human Tumor Cell Line Panel to Screen 2260 Cancer Drug Combinations to Generate >3 Million Data Points Used to Populate a Large Matrix of Anti-Neoplastic Agent Combinations (ALMANAC) Database.
    Close DA; Wang AX; Kochanek SJ; Shun T; Eiseman JL; Johnston PA
    SLAS Discov; 2019 Mar; 24(3):242-263. PubMed ID: 30500310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal drug combinations and minimal hitting sets.
    Vazquez A
    BMC Syst Biol; 2009 Aug; 3():81. PubMed ID: 19660129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods for High-throughput Drug Combination Screening and Synergy Scoring.
    He L; Kulesskiy E; Saarela J; Turunen L; Wennerberg K; Aittokallio T; Tang J
    Methods Mol Biol; 2018; 1711():351-398. PubMed ID: 29344898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computationally predicting clinical drug combination efficacy with cancer cell line screens and independent drug action.
    Ling A; Huang RS
    Nat Commun; 2020 Nov; 11(1):5848. PubMed ID: 33203866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
    Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
    J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.
    Ocaña A; Freedman O; Amir E; Seruga B; Pandiella A
    Cancer Metastasis Rev; 2014 Mar; 33(1):295-307. PubMed ID: 24338003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of well-established drugs targeting cancer metabolism: reproducibility of the efficacy of a highly effective drug combination in mice.
    Abolhassani M; Guais A; Sanders E; Campion F; Fichtner I; Bonte J; Baronzio G; Fiorentini G; Israël M; Schwartz L
    Invest New Drugs; 2012 Aug; 30(4):1331-42. PubMed ID: 21655919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug combination screening as a translational approach toward an improved drug therapy for chordoma.
    Scheipl S; Barnard M; Lohberger B; Zettl R; Brcic I; Liegl-Atzwanger B; Rinner B; Meindl C; Fröhlich E
    Cell Oncol (Dordr); 2021 Dec; 44(6):1231-1242. PubMed ID: 34550531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.
    Holbeck SL; Camalier R; Crowell JA; Govindharajulu JP; Hollingshead M; Anderson LW; Polley E; Rubinstein L; Srivastava A; Wilsker D; Collins JM; Doroshow JH
    Cancer Res; 2017 Jul; 77(13):3564-3576. PubMed ID: 28446463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
    Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
    Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets.
    Amzallag A; Ramaswamy S; Benes CH
    BMC Bioinformatics; 2019 Feb; 20(1):83. PubMed ID: 30777010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for advanced gastric cancer.
    Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
    Menden MP; Wang D; Mason MJ; Szalai B; Bulusu KC; Guan Y; Yu T; Kang J; Jeon M; Wolfinger R; Nguyen T; Zaslavskiy M; ; Jang IS; Ghazoui Z; Ahsen ME; Vogel R; Neto EC; Norman T; Tang EKY; Garnett MJ; Veroli GYD; Fawell S; Stolovitzky G; Guinney J; Dry JR; Saez-Rodriguez J
    Nat Commun; 2019 Jun; 10(1):2674. PubMed ID: 31209238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective drug combinations in breast, colon and pancreatic cancer cells.
    Jaaks P; Coker EA; Vis DJ; Edwards O; Carpenter EF; Leto SM; Dwane L; Sassi F; Lightfoot H; Barthorpe S; van der Meer D; Yang W; Beck A; Mironenko T; Hall C; Hall J; Mali I; Richardson L; Tolley C; Morris J; Thomas F; Lleshi E; Aben N; Benes CH; Bertotti A; Trusolino L; Wessels L; Garnett MJ
    Nature; 2022 Mar; 603(7899):166-173. PubMed ID: 35197630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism.
    Ruhnau J; Parczyk J; Danker K; Eickholt B; Klein A
    BMC Cancer; 2020 Jul; 20(1):617. PubMed ID: 32615946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.
    Schaffer M; Chaturvedi S; Davis C; Aquino R; Stepanchick E; Versele M; Liu Y; Yang J; Lu R; Balasubramanian S
    Leuk Lymphoma; 2018 Apr; 59(4):931-940. PubMed ID: 28750570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma.
    Grbovic-Huezo O; Pitter KL; Lecomte N; Saglimbeni J; Askan G; Holm M; Melchor JP; Chandwani R; Joshi S; Haglund C; Iacobuzio-Donahue CA; Chiosis G; Tammela T; Leach SD
    Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30670-30678. PubMed ID: 33199632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment.
    Xu F; Tong M; Tong CSW; Chan BKC; Chu HY; Wong TL; Fong JHC; Cheung MSH; Mak KH; Pardeshi L; Huang Y; Wong KH; Choi GCG; Ma S; Wong ASL
    Cancer Res; 2021 Dec; 81(24):6219-6232. PubMed ID: 34666996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.